Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EHA 2019 | iwCART: a union of CAR-Ters

David Maloney • 15 Jun 2019

EHA 2019

General

David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the aims and outcomes of the iwCART workshop being held in Miami this year at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

T-cell engagers and CAR T-cells in R/R CLL: clinical data and future directions

T-cell engagers and CAR T-cells in R/R CLL: clinical data and future directions

Alexey Danilov et al. • 11 Apr 2025

Expanding the CAR platform in NHL

Expanding the CAR platform in NHL

David Maloney et al. • 17 Oct 2023

Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…

Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…

David Maloney et al. • 30 Apr 2022

Advances in CAR-T therapy for lymphoma

Advances in CAR-T therapy for lymphoma

Caron Jacobson et al. • 1 May 2022

Related Videos

From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD

From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD

Iskra Pusic • 11 Sep 2026

Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML

Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML

Maher Salamoon • 8 Sep 2026

Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy

Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy

Michael Jain • 11 Sep 2026

Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality

Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality

Michael Jain • 11 Sep 2026